Anti-PD-L1 antibody [EPR20529],Abcam,AB213480
Anti-PD-L1 antibody [EPR20529] (ab213480) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in ICC/IF, IP and WB. Abcam's high quality manufacturing and validation processes ensure Anti-PD-L1 antibody [EPR20529] (ab213480) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. The specificity of Anti-PD-L1 antibody [EPR20529] (ab213480) has been confirmed by Western Blot testing in PD-L1 knockout MEF (mouse embryonic fibroblast) cells. Anti-PD-L1 antibody [EPR20529] (ab213480) has 5 independent reviews from customers. Anti-PD-L1 antibody [EPR20529] (ab213480) specifically detects PD-L1 (UniProt ID: Q9EP73; Molecular weight: 31kDa) and is sold in 100 µL and 1 mL selling sizes. Conjugation-ready, carrier free format available for antibody clone EPR20529 - ab223141 . Programmed death-ligand 1 (PD-L1) is a critical protein in immuno-oncology, playing a significant role in tumor immune evasion. It is expressed on the surface of tumor cells and binds to the PD-1 receptor on T cells, inhibiting their activity and allowing tumors to escape immune detection. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .
Host
Rabbit
Reactivity
Mouse
Application
IP, WB, ICC/IF
Platform ID
BAB917493858
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Plays a critical role in induction and maintenance of immune tolerance to self (PubMed : 11238124). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed : 11238124). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed : 11015443, PubMed : 12719480).. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed : 12218188, PubMed : 27281199). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (PubMed : 12218188). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (PubMed : 12218188). See full target information Cd274
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
- Products>Trial Size Antibodies
Please provide the required information below so that we can quickly source your products.